

MEDIA RELEASE



In case of any enquiry / clarification, please contact Mr. Jayesh Desai on +91 9824501396

Torrent Pharma announces Q1 FY20 results, Revenue up by 8% and EBITDA grows by 11%.

July 23rd, 2019

Torrent Pharmaceuticals Ltd ('TPL'), is ranked 7th in Indian Pharmaceuticals Market (without bonus units) and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), and Vitamins Minerals Nutritionals (VMN). It is specialty focused company with 75% of its revenue from chronic & sub-chronic therapies. It has presence in 40 countries and is ranked No. 1 amongst the Indian pharma Companies in Brazil, Germany and Philippines.

TPL has 8 manufacturing facilities (7 in India & 1 in US), of which 5 are USFDA approved. With R&D as backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists.

TPL continues to be focused on its specialty driven business, productivity improvement, brand building, maintaining high quality manufacturing practices and investments into R&D for a robust future pipeline.

Key highlights: Q1 FY20 consolidated financials

- Revenues at Rs 2,022 crores (YoY growth of 8%).
 - India business at Rs. 907 crores (up by 9% YoY). Base impact of discontinued products in previous year is 2%. Adjusted for this growth is 11%.
 - US revenues at Rs. 376 crores (up by 13% YoY). 3 ANDAs were filed during the quarter. As on June 30th 2019, 34 ANDAs are pending approval and 11 tentative approvals have been received.
 - Germany revenues at Rs. 262 crores (up by 4% YoY).
 - Brazil revenues at Rs. 174 crores (down by 3% YoY).
- Gross margins at 72%.
- EBITDA at Rs. 558 crores (EBITDA margin of 28%), up by 11% (YoY).
- Net profit at Rs. 216 crores as against Rs. 163 crores in Q1 FY19 (up by 33% YoY).
- R&D spend at Rs. 136 crores against Rs. 128 crores in Q1 FY19.

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 7,600 crores is the flagship Company of the Torrent Group. Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.